Clinical trial NCT07015164: Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy
Official title: Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: HIV
Keywords: HIV
antiretroviral treatment
viral reservoir
persistent viremia
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults living with HIV-1, under antiretroviral therapy (ART) for at least 2 years, recruited from a single clinical center. The study includes two groups: individuals with persistent low-level viremia and individuals with sustained virological suppression.

Brief summary: Low-level HIV replication in a patient on effective antiretroviral therapy is a relatively frequent event, generating stress for both patient and physician, due to the fear of subsequent virological escape with emergence of resistant virus(es) and/or transmission of such virus(es) to partner(s). Understanding the origin of this low-level viral replication would enable informed therapeutic decisions to be made (therapeutic intensification, modification of antiretroviral (ARV) treatment with the use of molecules belonging to other therapeutic classes, or maintenance of the status quo), and reassure patients of the scientific rationale guiding their course of action.

This is a single-center, cross-sectional study designed to compare the parameters of the cellular viral reservoir between a group of participants with persistent viral replication under ARV treatment and a group of participants with perfect viral replication control (stable virological suppression).

Patients meeting the eligibility criteria will be offered the opportunity to have two additional blood tubes taken for research purposes, as part of an integrated visit to monitor HIV infection, which already includes a venipuncture. Patients meeting these criteria will have been previously identified by a feasibility survey carried out by the clinical research team of the Infectious and Tropical Diseases Department (SMIT) at Hôpital Bichat-Claude Bernard (AP-HP. Nord).

Detailed description: The aim of antiretroviral (ARV) treatment is to inhibit viral replication in order to achieve an undetectable plasma viral load. The threshold of undetectability to be achieved differs from country to country and from learned societies to learned societies, and is set at 50 copies/mL at 6 months of treatment initiation in French recommendations (Morlat, 2018), 200 copies/mL in US recommendations (Thompson et al., 2021), and 1,000 copies/mL in recommendations published by the World Health Organization (WHO) (World Health Organization, 2016), the latter threshold being the one used by all resource-limited countries.

Currently, the vast majority of patients treated with ARVs are virologically suppressed, with viral load below the quantification threshold of the viral load technique (20 to 50 copies/mL, classically) (Elvstam et al., 2023). Nevertheless, a non-negligible percentage of patients, up to 10% in a recent American study (Fleming et al., 2019), may present persistent viremia (i.e., on several consecutive viral loads) of low level (between 51 and 1,000 copies/mL).The risk of persistent viral replication under antiretroviral pressure is to favor the emergence of resistance mutations, which can impact the activity of an ARV molecule or all the molecules in a therapeutic class (Assoumou et al., JAC, 2017; Elvstam et al., CID, 2023). The phenomenon of persistent plasma viremia has been shown to be more frequently observed with certain ARV classes such as protease inhibitors. However, few data are currently available on the most recent ARVs, such as 2nd-generation integrase inhibitors (INIs) and the most recent non-nucleoside reverse transcriptase inhibitor (NNRTI), doravirin. These latest-generation molecules have specific profiles. For example, 2nd-generation INIs present a high genetic barrier to resistance, while doravirine has the advantage of having a genotypic resistance profile distinct from other NNRTIs, and of diffusing well across compartments.

These persistent low levels of viremia raise numerous questions in terms of clinical management, and may lead to changes in therapy. We therefore need to better understand the mechanism(s) behind these persistent low viremia levels, so that we can provide the best possible care for PLWHA.However, in the absence of a clear explanation of the mechanism underlying this low-noise replication, management of this clinical situation is often difficult and sub-optimal. In fact, the therapeutic intensifications proposed (addition of a 4th agent or switch to another 3rd agent that does not exist as a single tablet) can complicate the patient's regimen, and therefore impact on compliance. At present, it is often proposed to closely monitor patients with persistent low viremia, which can be stressful for the patient, in addition to generating healthcare costs due to the close follow-up visits and biological tests prescribed.Various mechanisms could be at the root of this persistent low-level viremia: persistence of low-level viral replication, notably through release from anatomical reservoirs, clonal expansion of provirus-carrying cells that can be reactivated following polyclonal stimulation, or the production of non-infectious virus from mutation-carrying proviruses (Elvstam et al., 2019; Halvas et al., 2020; Simonetti et al., 2016) (Figure 2). These mechanisms are all linked to the particularity of the HIV cycle, which is the ability of its genome to integrate as double-stranded DNA into the cellular genome. This integrated viral DNA, also known as provirus, constitutes the reservoir. The vast majority of proviruses present in the cellular reservoir are defective, i.e. not replication-competent (Bender et al., 2019). Different types of mutations are responsible for these defective proviruses: i) the appearance of stop codons due to G-to-A mutations in the viral genome, selected by host immune pressure mechanisms such as the APOBEC (Apolipoprotein B mRNA-editing Enzyme Catalytic polypeptide-like) enzyme, ii) mutations in key regions, such as 5' LTR (Long Terminal Repeat), and iii) larger or smaller deletions of the proviral genome.A recent study compared plasma viruses with proviruses in 8 patients with persistent low plasma viremia (White et al., 2023). The proviral genomes that contributed to plasma viremia differed from proviral genomes not found in plasma viruses, notably in terms of integration sites in the human genome and transcriptomics in the CD4 cells that host them. This suggests that certain proviruses may be specifically responsible for low-noise viral replication. The mechanism by which these proviruses are activated is not determined, but could result from random reactivations due to higher levels of systemic inflammation and immune activation. Other work has suggested that clonal expansion of certain provirus-bearing CD4+ T cells may play a role in the persistence of low-level viremia (Simonetti et al., 2016). This clonal expansion is a random process and, in this scenario, the viruses produced might not generate new productive infections, due to effective ARV concentrations.In this study, we will explore different hypotheses concerning the origin of these persistent plasma viremias by studying the viral reservoir in patients with and without persistent low-level viremia, and by investigating the association between viral reservoir levels and different parameters of immune activation, inflammation and immune exhaustion.

Eligibility criteria: PLHIV with persistent low plasma viral load on ARV therapy :

* PLHIV \> 18 years of age
* On ARV treatment for at least 3 years
* Taking one of the following ARV treatments:

  * Tenofovir Alafenamide + Emtricitabine + Bictegravir
  * Abacavir + Lamivudine + Dolutegravir
  * Tenofovir Disoproxil Fumarate + Emtricitabine + Dolutegravir
  * Tenofovir Disoproxil Fumarate + Lamivudine

    + Doravirine
  * Abacavir + Lamivudine + Doravirine
* With at least 3 consecutive HIV plasma viral loads between 50 and 1,000 copies/mL over a period of at least 12 months
* Absence of resistance mutations to current antiretroviral treatments

PLHIV group with perfect control of viral replication (stable virological suppression):

* PLWH \> 18 years of age
* On ARV treatment for at least 3 years
* Taking one of the following ARV treatments:

  * Tenofovir Alafenamide + Emtricitabine + Bictegravir
  * Abacavir + Lamivudine + Dolutegravir
  * Tenofovir Disoproxil Fumarate + Emtricitabine + Dolutegravir
  * Tenofovir Disoproxil Fumarate + Lamivudine

    + Doravirine
  * Abacavir + Lamivudine + Doravirine
* With at least 3 plasma HIV viral loads below 50 copies/mL over a period of at least 24 months
* Absence of resistance mutations to current antiretroviral treatments

Primary outcomes:
measure: Quantification of HIV-1 cellular reservoir parameters using molecular techniques
timeFrame: At study inclusion (single blood sample)
Secondary outcomes:
measure: Genetic diversity of HIV-1 proviruses integrated in cellular genomes
timeFrame: At study inclusion (single blood sample)
measure: Phylogenetic analysis of plasma HIV-1 sequences
timeFrame: At study inclusion (single blood sample)
measure: Expression levels of immune activation and exhaustion markers on CD4+ and CD8+ T cells
timeFrame: At study inclusion (single blood sample)
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Bichat, service des Maladies Infectieuses et Tropicales
Study officials:
References: